UM-Chor1 (ATCC® CRL-3270)

Organism: Homo sapiens, human  /  Cell Type: mesenchymal  /  Tissue: clivus  /  Disease: chordoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue clivus
Cell Type mesenchymal
Product Format frozen 1.0 mL
Morphology epithelial-like
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease chordoma
Age 64 years old
Gender male
Ethnicity Caucasian
Applications

This cell line may be used in the development of treatments and identifiable therapeutic targets for chordoma cancers

The Chordoma Foundation can offer financial assistance for the purchase of this cell line. Please contact cells@chordoma.org for more information.

Storage Conditions liquid nitrogen vapor phase
Images
Derivation Excised tumor tissue was digested and plated. The resultant cultures were purified by flow cytometry and the population of cells staining positive for neural cell adhesion molecule (NCAM) were expanded as the UM-Chor1 chordoma cell line.
Antigen Expression CD34 +, Brachyury + (Owen JH, et al.)
Tumorigenic Yes, in NOD/SCID mice (Owen JH, et al.)
Comments

UM-Chor1 is the first known human clival chordoma established. It exhibits chordoma-like characteristics and has molecular, genetic, and morphological features typical of chordoma. This cell line was established from a suprasellar lesion with solid, cystic, and hemorrhagic components. It extended along the clivus, and into the ethmoid sinuses. Chordoma is a rare slow growing tumor type, and UM-Chor1 is a relatively slow growing cell line. The cells express the transcription factor T (Brachyury) that is the most specific marker for chordoma. This cell line was accessioned with the support of the Chordoma Foundation, a nonprofit organization working to improve the lives of chordoma patients by accelerating research to develop effective treatments for the chordoma disease. This rare chordoma cell line can be a useful tool for studying the diversity of primary tumors of the spinal chord.

This cell line was accessioned with the support of the Chordoma Foundation, a non-profit organization working to improve the lives of chordoma patients by accelerating research to develop effective treatments for the chordoma disease.

Complete Growth Medium The base medium for this cell line is a 4:1 mixture of ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005 and ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following component to the base medium:
  • fetal bovine serum to a final concentration of 10%

Subculturing
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. 
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
    Cultures can be established between 2 x 104 and 4 x 104 viable cells/cm2.
  6. Incubate cultures at 37°C.
Interval: Maintain cultures at a cell concentration between 1 x 105 to 2 x 105 cell/cm2.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation Complete Culture Medium, 90%; DMSO, 10%
Culture Conditions Temperature: 37┬░C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5%
Volume 1.0 mL
STR Profile
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 12
D16S539: 12
D5S818: 9,13
D7S820: 11
THO1: 7,9.3
TPOX: 8,9
vWA: 15
Sterility Tests Bacteria and Yeast: No growth
Mycoplasma: No growth
Viral Testing Hepatitis B: None detected
Cytomegalovirus: None detected
Human immunodeficiency virus: None detected
Epstein-Barr virus: None detected
Human papillomavirus: None detected
Passage Number 43
Population Doubling Time About 5 days (Chordoma Foundation Cell Line Validation Service)
Name of Depositor M Prince and J Owen (University of Michigan)
Year of Origin 2012
References

Owen JH, et al. Establishment and characterization of two novel human chordoma cell lines. Annual Meeting of American Head and Neck Society 2014 Poster

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Owen JH, et al. Establishment and characterization of two novel human chordoma cell lines. Annual Meeting of American Head and Neck Society 2014 Poster